Filtered By:
Drug: Lamictal

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 50 results found since Jan 2013.

Migraine Prophylaxis, Ischemic Depolarizations, and Stroke Outcomes in Mice Basic Sciences
Conclusions— These data underscore the importance of hyperexcitability as a mechanism for increased stroke risk in migraineurs, and suggest that migraine prophylaxis may not only prevent migraine attacks but also protect migraineurs against ischemic injury.
Source: Stroke - December 22, 2014 Category: Neurology Authors: Eikermann-Haerter, K., Lee, J. H., Yalcin, N., Yu, E. S., Daneshmand, A., Wei, Y., Zheng, Y., Can, A., Sengul, B., Ferrari, M. D., van den Maagdenberg, A. M. J. M., Ayata, C. Tags: Neuroprotectors Basic Sciences Source Type: research

Increased risk of stroke and myocardial infarction in patients with epilepsy: A systematic review of population-based cohort studies.
CONCLUSIONS: Patients with epilepsy are at higher risk of subsequent stroke and MI in comparison with subjects without epilepsy. Although individual AEDs may carry different risks of cardio- and cerebrovascular disease, the clinical relevance of the metabolic effects of the enzyme-inducing AEDs is still uncertain. This article is part of the Special Issue "Seizures & Stroke. PMID: 31182394 [PubMed - as supplied by publisher]
Source: Epilepsy and Behaviour - June 6, 2019 Category: Neurology Authors: Brigo F, Lochner P, Nardone R, Manganotti P, Lattanzi S Tags: Epilepsy Behav Source Type: research

Mood stabilisers and risk of stroke in bipolar disorder.
CONCLUSIONS: Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder.Declaration of interestNone. PMID: 30295208 [PubMed - as supplied by publisher]
Source: The British Journal of Psychiatry for Mental Science - October 10, 2018 Category: Psychiatry Tags: Br J Psychiatry Source Type: research

Increased risk of stroke and myocardial infarction in patients with epilepsy: A systematic review of population-based cohort studies
ConclusionsPatients with epilepsy are at higher risk of subsequent stroke and MI in comparison with subjects without epilepsy. Although individual AEDs may carry different risks of cardio- and cerebrovascular disease, the clinical relevance of the metabolic effects of the enzyme-inducing AEDs is still uncertain.This article is part of the Special Issue “Seizures & Stroke
Source: Epilepsy and Behavior - June 8, 2019 Category: Neurology Source Type: research

Misdiagnosis of lamotrigine toxicity as posterior circulation transient ischemic attack or stroke.
CONCLUSION: Emergency departments will frequently call a stroke alert for patients taking LTG and presenting with symptoms consistent with LTG toxicity, particularly in seniors at greater risk of stroke. This adds not only expense but also radiation and contrast exposure from computed tomography (CT) studies. We recommend that a rapid LTG assay be made available and always ordered in patients receiving LTG, avoiding the considerable expense of an unnecessary stroke evaluation. PMID: 32652284 [PubMed - as supplied by publisher]
Source: Epilepsy and Behaviour - July 7, 2020 Category: Neurology Authors: Ramey P, Osborn M, Kirshner H, Abou-Khalil B Tags: Epilepsy Behav Source Type: research

Pharmacotherapy to Manage Central Post-Stroke Pain
AbstractCentral post-stroke pain is a chronic neuropathic pain syndrome following a cerebrovascular accident. The development of central post-stroke pain is estimated to occur in 8 to 55% of stroke patients and is described as constant or intermittent neuropathic pain accompanied by dysesthesia of temperature and/or pressure sensations. These pain and sensory deficits are within the area of the body corresponding to the stroke lesion. The onset of pain is usually gradual, though it can develop either immediately after stroke or years after. Given the diversity in its clinical presentation, central post-stroke pain is a cha...
Source: CNS Drugs - February 7, 2021 Category: Neurology Source Type: research

Pharmacological Management of Central Post-Stroke Pain: A Practical Guide
Abstract Pain is one of the most troublesome sequelae of stroke. Some of this post-stroke pain is caused by the brain lesion itself; this is called central post-stroke pain (CPSP). Although the prevalence of CPSP is low (1–8 %), persistent, often treatment-resistant, painful sensations are a major problem for stroke patients. The pathogenesis of CPSP remains unknown, but suggested underlying causes include hyperexcitation in the damaged sensory pathways, damage to the central inhibitory pathways, or a combination of the two. For pharmacological treatment, amitriptyline, an adrenergic antidepressant, is current...
Source: CNS Drugs - September 1, 2014 Category: Neurology Source Type: research

Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis
ConclusionsClinicians should look for any evidence of central neuropathic pain for at least 12  months after stroke. Both pharmacological and non-pharmacological interventions can be used for the management of CPSP. Lamotrigine has the strongest evidence (Level II of evidence, derived from small randomized controlled trials) for being effective in the management of CPSP. Future research sho uld focus on well-designed trials of pharmacological and non-pharmacological interventions aiming to relief CPSP, which is a very common but often neglected pain syndrome.
Source: Advances in Therapy - May 22, 2020 Category: Drugs & Pharmacology Source Type: research

Epilepsia Partialis Continua Secondary To Ischemic Stroke, Responsive To The Combination Of Levetiracetam And Lacosamide (P4.255)
CONCLUSIONS: EPC represents a condition commonly refractory to AED. We report two cases of EPC secondary to subacute and chronic IS that showed responsiveness to the combination of levetiracetam and lacosamide. Further evaluation of this AED combination in treating this difficult condition is needed.Disclosure: Dr. Thompson has nothing to disclose. Dr. Murr has nothing to disclose. Dr. Fayad has received research support from the National Institute of Neurological Disorders and Stroke, and St Jude Medical.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Thompson, R., Murr, N., Fayad, P. Tags: Epilepsy and Clinical Neurophysiology (EEG): Status Epilepticus Source Type: research

A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury
This study evaluated efficacy of the combination of three clinically approved drugs: lamotrigine, minocycline, and lovastatin, using two mouse models: global and focal cerebral ischemia induced by transient occlusion of the common carotid arteries or the middle cerebral artery, respectively. In vitro, the combination drug, but not single drug, protected neurons against oxygen-glucose deprivation (OGD)-induced cell death. The combination drug simultaneously targeted cell apoptosis and DNA damage induced by ischemia. Besides acting on neurons, the combination drug suppressed inflammatory processes in microglia and brain endo...
Source: Translational Stroke Research - June 17, 2017 Category: Neurology Source Type: research

Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study.
CONCLUSIONS: The LEV administration is associated with lower mortality in patients with MELAS in this retrospective study. Further laboratory research and prospective cohort studies are needed to confirm whether LEV has neuroprotective effects on patients with mitochondrial diseases. PMID: 30681492 [PubMed - in process]
Source: Chinese Medical Journal - January 27, 2019 Category: General Medicine Authors: Zhang Z, Zhao DH, Zhao XT, Zhang X, Xiong H, Bao XH, Yuan Y, Wang ZX Tags: Chin Med J (Engl) Source Type: research

Although pharmacological treatment may have beneficial effects in central post-stroke pain, it does not abolish the symptoms
Abstract The management of central post-stroke pain is challenging. Amitriptyline is considered the first-line pharmacological choice, with lamotrigine, gabapentin and pregabalin used as alternative therapies. If the therapeutic response with monotherapy is insufficient, combination therapy (e.g. an adrenergic antidepressant plus an antiepileptic) may be considered.
Source: Drugs and Therapy Perspectives - February 4, 2015 Category: Drugs & Pharmacology Source Type: research

Randomized Controlled Trials of Antiepileptic Drugs for the Treatment of Post-stroke Seizures: a Systematic Review with Network Meta-analysis
ConclusionsDirect and indirect comparisons did not find a difference in seizure freedom between the various AEDs, probably because of the small number of patients included. LEV and LTG appears better tolerated than CR-CBZ and LEV seems associated with more AEs than LTG. Further studies are required to provide robust evidence on efficacy and tolerability of AEDs for treating poststroke epilepsy.
Source: Seizure - August 4, 2018 Category: Neurology Source Type: research

The Outcome of Status Epilepticus and Long-Term Follow-Up
Conclusion: This study highlights the importance of regular care and patient follow-up. Introduction Status epilepticus (SE) is a condition and most extreme form of epilepsy (1), which leads to abnormal and prolonged seizure (at least 5 min). In case SE persists over 30 min, it may have severe long-term consequences (2). Referring to the new classification scheme of SE, there are two operational dimensions of the definition: time point 1 (T1) is associated with abnormally prolonged seizure, when therapy should be initiated, while time point 2 (T2) is related to the time of on-going seizure activity involving a risk...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Poststroke epilepsy: update and future directions
Stroke is among the most common causes of epilepsy after middle age. Patients with poststroke epilepsy (PSE) differ in several respects from patients with other forms of structural–metabolic epilepsy; not least in age, age-related sensitivity to side effects of antiepileptic drugs (AEDs), and specific drug–drug interaction issues related to secondary-stroke prophylaxis. Encouragingly, there has lately been remarkable activity in the study of PSE. Three developments in PSE research deserve particular focus. First, large prospective trials have established the incidence and risk factors of PSE in the setting of m...
Source: Therapeutic Advances in Neurological Disorders - August 14, 2016 Category: Neurology Authors: Zelano, J. Tags: Reviews Source Type: research